Alkermes plc
Revenue Breakdown
| Fiscal Year | VIVITROL | ARISTADA and ARISTADA INITIO | LYBALVI | Product sales net (unspecified product) | Manufacturing and royalty revenues | Manufacturing revenues | Royalty revenues | License revenue | Research and development revenue | Net collaborative profit |
|---|---|---|---|---|---|---|---|---|---|---|
| FY2009 | $0 | $0 | $0 | $4.5M | $0 | $116.8M | $33.2M | $0 | $42.1M | $130.2M |
| FY2010 | $0 | $0 | $0 | $20.2M | $0 | $112.9M | $37.0M | $0 | $3.1M | $5.0M |
| FY2011 | $0 | $0 | $0 | $28.9M | $0 | $118.5M | $38.3M | $0 | $880.0K | $0 |
| FY2012 | $0 | $0 | $0 | $41.2M | $326.4M | $0 | $0 | $0 | $22.3M | $0 |
| FY2013 | $0 | $0 | $0 | $58.1M | $510.9M | $0 | $0 | $0 | $6.5M | $0 |
| FY2014 | $0 | $0 | $0 | $94.2M | $516.9M | $0 | $0 | $0 | $7.8M | $0 |
| FY2015 | $0 | $0 | $0 | $149.0M | $475.3M | $0 | $0 | $0 | $4.0M | $0 |
| FY2016 | $209.0M | $47.2M | $0 | $0 | $487.2M | $0 | $0 | $0 | $2.3M | $0 |
| FY2017 | $269.3M | $93.5M | $0 | $0 | $505.3M | $0 | $0 | $28.0M | $7.2M | $0 |
| FY2018 | $302.6M | $147.7M | $0 | $0 | $526.7M | $0 | $0 | $48.4M | $68.9M | $0 |
| FY2019 | $335.4M | $189.1M | $0 | $0 | $447.9M | $0 | $0 | $145.8M | $52.8M | $0 |
| FY2020 | $310.7M | $241.0M | $0 | $0 | $484.0M | $0 | $0 | $1.1M | $1.9M | $0 |
| FY2021 | $343.9M | $275.4M | $8.2M | $0 | $541.8M | $0 | $0 | $3.5M | $1.0M | $0 |
| FY2022 | $379.5M | $302.1M | $96.0M | $0 | $332.0M | $0 | $0 | $2.0M | $260.0K | $0 |
| FY2023 | $400.4M | $327.7M | $191.9M | $0 | $743.4M | $0 | $0 | $0 | $19.0K | $0 |
| FY2024 | $457.3M | $346.2M | $280.0M | $0 | $474.1M | $0 | $0 | $0 | $3.0K | $0 |
| FY2025 | $467.9M | $370.0M | $346.7M | $0 | $291.3M | $0 | $0 | $0 | $0 | $0 |